Innovate Biopharmaceuticals (INNT) Hits New 52-Week Low at $2.35
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $2.35 and last traded at $2.42, with a volume of 2312 shares traded. The stock had previously closed at $2.83.
Several equities research analysts have issued reports on the company. Zacks Investment Research cut Innovate Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. ValuEngine raised Innovate Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 22nd. Finally, HC Wainwright set a $35.00 target price on Innovate Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 24th.
Innovate Biopharmaceuticals (NASDAQ:INNT) last posted its earnings results on Tuesday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. On average, equities research analysts forecast that Innovate Biopharmaceuticals Inc will post -1.24 EPS for the current fiscal year.
About Innovate Biopharmaceuticals (NASDAQ:INNT)
Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease.
Featured Article: Swap
Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.